Literature DB >> 17017971

Pharmacophore models for metabotropic 5-HT receptor ligands.

Andrzej J Bojarski1.   

Abstract

An overview of pharmacophore models, developed for different subtypes of serotonin receptors belonging to the GPCR family, is presented. Starting with early models for 5-HT1A and 5-HT2 receptor ligands, and ending with the latest ones for 5-HT6- and 5-HT7 receptors, as many as fifty others are briefly summarized. No models have been developed for 5-HT1F-, 5-HT2B- and 5-HT5B receptor ligands, and in the case of 5-HT1E- and 5-HT5A Rs only single pilot studies with non-selective tryptamine derivatives are reported. For all the other subtypes of 5-HTRs, various pharmacophore hypotheses--either qualitative and/or quantitative--are characterized by sets of ligands used for their generation, a templates for alignment, the computational methods applied and, eventually, interfeature distances and/or statistical results--if available.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17017971     DOI: 10.2174/156802606778522186

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  9 in total

1.  Classification of 5-HT(1A) receptor agonists and antagonists using GA-SVM method.

Authors:  Xue-lian Zhu; Hai-yan Cai; Zhi-jian Xu; Yong Wang; He-yao Wang; Ao Zhang; Wei-liang Zhu
Journal:  Acta Pharmacol Sin       Date:  2011-10-03       Impact factor: 6.150

2.  Affinity of aporphines for the human 5-HT2A receptor: insights from homology modeling and molecular docking studies.

Authors:  Stevan Pecic; Pooja Makkar; Sandeep Chaudhary; Boojala V Reddy; Hernan A Navarro; Wayne W Harding
Journal:  Bioorg Med Chem       Date:  2010-06-20       Impact factor: 3.641

3.  Differential effects of 5-HT(2A) and 5-HT(2C) receptor blockade on strategy-switching.

Authors:  Phillip M Baker; Jennifer L Thompson; John A Sweeney; Michael E Ragozzino
Journal:  Behav Brain Res       Date:  2011-01-12       Impact factor: 3.332

4.  From Homology Models to a Set of Predictive Binding Pockets-a 5-HT1A Receptor Case Study.

Authors:  Dawid Warszycki; Manuel Rueda; Stefan Mordalski; Kurt Kristiansen; Grzegorz Satała; Krzysztof Rataj; Zdzisław Chilmonczyk; Ingebrigt Sylte; Ruben Abagyan; Andrzej J Bojarski
Journal:  J Chem Inf Model       Date:  2017-01-18       Impact factor: 4.956

5.  Synthesis and structure evaluation of new complex butylarylpiperazin-1-yl derivatives.

Authors:  Daniel Szulczyk; Anna Bielenica; Michał A Dobrowolski; Lukasz Dobrzycki; Mariola Krawiecka; Bożena Kuran; Marta Struga
Journal:  Med Chem Res       Date:  2013-09-03       Impact factor: 1.965

6.  Average Information Content Maximization--A New Approach for Fingerprint Hybridization and Reduction.

Authors:  Marek Śmieja; Dawid Warszycki
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

7.  Model structure-activity relationship studies of potential tropane 5HT1A, 5HT2A, and D2 receptor ligands.

Authors:  Tomasz Słowiński; Jacek Stefanowicz; Martyna Z Wróbel; Franciszek Herold; Andrzej Mazurek; Franciszek Pluciński; Aleksander P Mazurek; Irena Wolska
Journal:  Med Chem Res       Date:  2012-11-11       Impact factor: 1.965

8.  A linear combination of pharmacophore hypotheses as a new tool in search of new active compounds--an application for 5-HT1A receptor ligands.

Authors:  Dawid Warszycki; Stefan Mordalski; Kurt Kristiansen; Rafał Kafel; Ingebrigt Sylte; Zdzisław Chilmonczyk; Andrzej J Bojarski
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

9.  Computer-Aided Studies for Novel Arylhydantoin 1,3,5-Triazine Derivatives as 5-HT₆ Serotonin Receptor Ligands with Antidepressive-Like, Anxiolytic and Antiobesity Action In Vivo.

Authors:  Rafał Kurczab; Wesam Ali; Dorota Łażewska; Magdalena Kotańska; Magdalena Jastrzębska-Więsek; Grzegorz Satała; Małgorzata Więcek; Annamaria Lubelska; Gniewomir Latacz; Anna Partyka; Małgorzata Starek; Monika Dąbrowska; Anna Wesołowska; Claus Jacob; Katarzyna Kieć-Kononowicz; Jadwiga Handzlik
Journal:  Molecules       Date:  2018-10-03       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.